




# First Quarter 2022 Business Update

May 10, 2022

PARIS: IPH.PA

NASDAQ: IPHA



# Disclaimer on Forward-Looking Information and Risk Factors



This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed.

This document contains forward-looking statements. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to various risks and uncertainties, which could cause the Company’s actual results or financial condition to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document filed with the Autorité des Marchés Financiers (“AMF”), available on the AMF website ([www.amf-france.org](http://www.amf-france.org)) or on the Company’s website ([www.innate-pharma.com](http://www.innate-pharma.com)), and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2021, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company. Such documents may not be necessarily up to date.

This document contains data pertaining to the Company’s potential markets and the industry and environment in which it operates. Some of this data comes from external sources that are recognized in the field or from Company’s estimates based on such sources.

This presentation discusses product candidates that are under clinical development and which have not yet been approved for marketing by the U.S. Food and Drug Administration or the European Medicines Agency. No representation is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied.

The information contained herein has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. The Company is under no obligation to keep current the information contained in this presentation and any opinion expressed is subject to change without notice.

The Company shall not bear any liability whatsoever for any loss arising from any use of this document or its contents or otherwise arising in connection therewith.

This document and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares of the Company in any country.

# Speakers on Today's Call



**Mondher Mahjoubi, MD**  
*Chief Executive Officer  
Chairman of the Executive Board*




**Joyson Karakunnel, MD, MSc, FACP**  
*EVP, Chief Medical Officer*



**Yannis Morel, PhD**  
*EVP, Business Development and  
Product Portfolio Strategy*



**Frédéric Lombard, MBA**  
*SVP, Chief Financial Officer  
(Q&A)*



## Drive near-term value with Lacutamab

- TELLOMAK all comers cohort opened
- Announced data-driven clinical development plan for PTCL
- Preliminary Phase 2 data due in H2 2022



## Advance our innovative R&D pipeline

- IPH6101 ANKET™ Phase 1 trial underway
- IPH65 ANKET™ progress towards IND




## Build sustainable business through partnerships

- PACIFIC-9 Phase 3 NSCLC start
- \$50M milestone received
- AACR Phase 2 NeoCOAST data
- NeoCOAST-2 trial underway

# PACIFIC-9, Phase 3 clinical trial with monalizumab in NSCLC


*\$50 million milestone payment received from AstraZeneca on first patient dosed in Phase 3 trial, PACIFIC-9*



- ### Royalties
- AstraZeneca will record all sales of Monalizumab and will pay Innate double-digit royalties based on net sales to market.
  - In Europe, the agreement includes a co-promotion right for Innate and a 50% profit sharing in the territory
  - Innate Pharma will contribute 30% of the funding for Phase III clinical trials, with a pre-defined limit

**\$450 million received to date from AstraZeneca for monalizumab agreement**

# Our Robust Pipeline of Proprietary & Partnered Assets

Program	Target	Indication	Pre-Clinical	Phase 1	Phase 2	Phase 3	Status
<b>Lacutamab</b>	KIR3DL2	Sézary Syndrome	TELLOMAK PHASE 2 (FDA FAST TRACK/EMA PRIME DESIGNATION)				Preliminary Phase 2 data expected 2022
		Mycosis Fungoides	TELLOMAK PHASE 2				Early data presented Preliminary Phase 2 data expected 2022
		PTCL (combo with GemOx)	PHASE 2				Phase 2 start H2 2021
		PTCL (mono)	PHASE 1b				Phase 1 start H2 2021
<b>Monalizumab*</b>	NKG2A	Post-PDx HNSCC	INTERLINK-1 PHASE 3				Phase 3 data expected 2022+*
		Unresectable Stg III NSCLC	PACIFIC-9 PHASE 3				Phase 3 starting
		Neoadjuvant NSCLC, other	NeoCOAST-2 PHASE 2				Phase 2 study in progress
<b>Avdoralimab</b>	C5aR	BP			PHASE 2		Data expected 2024
<b>IPH5201*</b>	CD39	Cancer (solid tumors)		PHASE 1			Data expected 2023
<b>IPH5301</b>	CD73	Cancer (solid tumors)		PHASE 1			Phase 1 study in progress
 <b>ANKET™</b> <small>antibody-based NK cell Engage Therapeutics</small>		IPH6101** (CD123 tri-specific)		PHASE 1			IPH6101 Phase 1 study in progress
		IPH62* (tri-specific)					Progress towards IND-enabling studies
		IPH64** (tri-specific)		Pre-clinical			
		IPH65 (tetra-specific)		Pre-clinical			
<b>Other preclinical</b>		IPH25*, IPH26* (Siglec-9), IPH43* (MICA/B ADC), IPH45		Pre-clinical			

GemOx: gemcitabine and oxaliplatin; PDx: anti-PD-1/L1; HNSCC: Squamous Cell Carcinoma of the Head and Neck; BP: Bullous Penphigoid; PTCL: Peripheral T Cell Lymphoma; IND: Investigational new drug

# TELLOMAK Phase 2 Study in Two CTCL Subtypes

*Potential for Sézary syndrome cohort to serve as pivotal trial*

Sézary Syndrome (N~60)  
≥ 2 prior systemic therapies

## Cohort 1

All comers, SS, must include mogalizumab as prior therapy

*Enrollment ongoing;  
Preliminary data expected in H2 2022*

Mycosis Fungoides (N~100)  
≥ 2 prior systemic therapies

## Cohort 2<sup>#</sup>

KIR3DL2+  
Simon 2 Stage

## Cohort 3<sup>#</sup>

KIR3DL2-  
Simon 2 Stage

## All Comers\*

KIR3DL2+/-

*Cohort 2 advanced to Stage 2; Cohort 3 did not progress to Stage 2. Preliminary Stage 1 data presented in 2021. Preliminary data expected in H2 2022*

## STUDY ENDPOINTS

- Primary endpoint: objective response rate
- Key secondary endpoints: progression-free survival, duration of response, quality of life and adverse events

## TARGET EXPRESSION

- KIR3DL2 +/-expression is defined as ≥1% using central evaluation of KIR3DL2 by immunohistochemistry
- \*FFPE based Companion Diagnostic under development
- # Frozen assay

# Developing a New Standard of Care Across KIR3DL2-Expressing T-Cell Lymphomas

## Cutaneous T-Cell Lymphoma (CTCL)

## Peripheral T-Cell Lymphoma (PTCL)

### Phase 2 TELLOMAK Trial

#### Sezary Syndrome

**80-200 patients**

>90% KIR3DL2 expression

- Trial expanded (pivotal potential)
- Fast Track & PRIME Designation
- Preliminary data expected in 2022 (H2)

#### Mycosis Fungoides

**2,200-4,400 patients**

~50% KIR3DL2 expression

- Advanced Cohort 2 to Stage 2 with earlier-than-expected efficacy signal
- 2 active cohorts – KIR3DL2 expressing and all comers
- Reported preliminary Cohort 2, Stage 1 data at ICML – 35% ORR
- Preliminary data expected in 2022 (H2)

#### Multi-trial Strategy From Relapsed to Frontline PTCL


**~18,000 patients**

~50% KIR3DL2 expression

- Monotherapy + combination with GemOX (LYSA) & SOC in relapsed setting
- Follow data into earlier lines (in combination with CHOP)

# Monalizumab: Early NSCLC

Phase 3 program underway, sponsored by AstraZeneca, for patients with unresectable, Stage III NSCLC



# Monalizumab: Head and Neck cancer

Innate's first Phase 3 program, sponsored by AstraZeneca, for patients with IO-pretreated SCCHN

**SCCHN**  
2L+ Phase 3 trial underway

**R/M SCCHN**

1L


2L+

**Phase 2 Cohort 3**  
1L R/M SCCHN  
monalizumab + durvalumab + cetuximab  
Data presented

**Phase 2 Cohort 2**  
Post PDx R/R SCCHN  
monalizumab + cetuximab  
Data presented



**Phase 3 INTERLINK-1\***  
Post PDx R/R SCCHN  
monalizumab + cetuximab  
Data expected 2024




Source: André, Vivier et al., Cell 2018

*Illustrative*

# Adenosine Pathway: IPH5201(anti CD39) and IPH5301 (anti CD73)

*Clinical trials underway*



## IPH5201\* (anti CD39): Phase 1 clinical trial design

Monotherapy IPH5201  
PART 1

Combination  
IPH5201 + durvalumab  
PART 2

## IPH5301 (anti CD73): Design of the Phase 1 clinical trial ISS CHANCES

Dose Escalation  
IPH5301

Extension  
IPH5301 + paclitaxel +  
trastuzumab

# ANKET™: Innate's Proprietary NK Cell Engager Platform



**is a versatile, fit-for-purpose technology** that is creating **an entirely new class** of tri- and tetra-specific molecules to induce synthetic immunity against cancer




Harnesses NK cell effector functions against cancer cells, through the most conserved activating receptor on NK cells: NKp46



Provides proliferation and activation signals targeted to NK cells



Demonstrates better anti-tumor efficacy than approved benchmark antibodies in preclinical tumor models



# Key Newsflow Over the Next 2 Years

2022

## Data Readouts

- Monalizumab NeoCOAST Ph2 NSCLC (AstraZeneca) AACR
- Lacutamab Phase 2 MF data (preliminary) H2
- Lacutamab Phase 2 SS data (preliminary) H2

## Clinical Progress

- Monalizumab PACIFIC-9 NSCLC Phase 3 start (AstraZeneca)
- Monalizumab NeoCOAST-2 Phase 2 start (AstraZeneca)
- Lacutamab r/r PTCL mono Phase 1b starting
- Lacutamab r/r PTCL combo Phase 2 starting (IST)
- IPH5201 (CD39) next step planning (AstraZeneca)
- IPH5301 (CD73) Phase 1 start (IST)
- Proprietary tetra-specific IPH65 ANKET™ progress towards IND

2023

## Data Readouts

- Lacutamab Phase 2 MF data (final)
- Lacutamab Phase 2 SS data (final)
- Lacutamab PTCL data (preliminary)
- IPH5201 (CD39) Phase 1 data (AstraZeneca)

## Clinical Progress


- Lacutamab PTCL next steps
- Proprietary tetra-specific IPH65 ANKET™ IND filing

# Early R&D Focus to Drive Value Through Later Stage Partnerships



## Lacutamab

- TELLOMAK read-out with MF in 2021 and preliminary data for MF and SS in 2022
- Initiating monotherapy and combination PTCL studies



## R&D pipeline

- Advancing proprietary tetra-specific NK cell-targeted platform and portfolio
- Advancing our adenosine franchise



## Partnerships

- Strong Phase 3 monalizumab collaboration with AstraZeneca
- Sanofi CD123 tri-specific Phase 1 clinical trial underway

**Cash with runway into 2024 with of €131.7 million\* as of March 31, 2022  
(In addition there is \$50 million in milestone payments from AstraZeneca)**




# Questions and Answers



# Monalizumab : NSCLC

2021 and AACR 2022 data presentations provide rationale for further exploration in NSCLC

COAST: Phase 2 study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC



NeoCOAST: open-label, randomized, Phase 2, multidrug platform study of neoadjuvant durvalumab alone or combined with novel agents in patients with resectable, early-stage (I to IIIA) non-small-cell lung cancer

